Cargando…

Personalized peptide vaccination for advanced colorectal cancer

We have developed a novel approach in cancer immunotherapy, the personalized peptide vaccination (PPV), in which human leukocyte antigen (HLA)-matched peptides are selected on the basis of preexisting host immunity before vaccination. Recently, we demonstrated the feasibility of PPV in previously tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasada, Tetsuro, Kibe, Shiro, Akagi, Yoshito, Itoh, Kyogo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485709/ https://www.ncbi.nlm.nih.gov/pubmed/26155407 http://dx.doi.org/10.1080/2162402X.2015.1005512

Ejemplares similares

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients
por: Takahashi, Ryuji, et al.
Publicado: (2014)

Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine
por: Yutani, Shigeru, et al.
Publicado: (2013)

Association of haptoglobin genetic polymorphism with overall survival in advanced castration-resistant prostate cancer patients with personalized peptide vaccination
por: Komatsu, Nobukazu, et al.
Publicado: (2013)

Personal neoantigen cancer vaccines: The momentum builds
por: Fritsch, Edward F, et al.
Publicado: (2014)

Cell-penetrating peptides—the Swiss Army knife of cancer vaccines
por: Walker, Paul R., et al.
Publicado: (2015)

Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer
por: Uchino, Yoshihiro, et al.
Publicado: (2021)

Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines
por: Saku, Shuko, et al.
Publicado: (2021)

Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens
por: Aruga, Atsushi
Publicado: (2013)

Targeting the tumor mutanome for personalized vaccination therapy
por: Kreiter, Sebastian, et al.
Publicado: (2012)

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
por: Noguchi, Masanori, et al.
Publicado: (2013)

Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
por: Yutani, Shigeru, et al.
Publicado: (2017)

Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard
por: Hailemichael, Yared, et al.
Publicado: (2013)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies
por: Binder, David C, et al.
Publicado: (2013)

An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1)
por: Chiang, Shu-Fen, et al.
Publicado: (2021)

Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination
por: Dosset, Magalie, et al.
Publicado: (2013)

Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
por: Gungor, Bilgi, et al.
Publicado: (2014)

Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
por: Suekane, Shigetaka, et al.
Publicado: (2017)

Production of epitope-specific antibodies using peptide-CpG-ODN-liposome complex without carriers and their application as a cancer vaccine in mice
por: Lee, YoungHee, et al.
Publicado: (2012)

The colorectal cancer immune paradox revisited
por: Angelova, Mihaela, et al.
Publicado: (2015)

Macrophages: Good guys in colorectal cancer
por: Edin, Sofia, et al.
Publicado: (2013)

Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination
por: Sakamoto, Shinjiro, et al.
Publicado: (2015)

A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer
por: Shirahama, Takahisa, et al.
Publicado: (2017)

TEIPP peptides: exploration of unTAPped cancer antigens
por: Marijt, Koen A., et al.
Publicado: (2019)

Hunting for clues: Regulatory T cells and colorectal cancer
por: Gallimore, Awen, et al.
Publicado: (2012)

LPCAT2 controls chemoresistance in colorectal cancer
por: Cotte, Alexia Karen, et al.
Publicado: (2018)

Multiverse of immune microenvironment in metastatic colorectal cancer
por: Van den Eynde, Marc, et al.
Publicado: (2020)

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients
por: Yutani, Shigeru, et al.
Publicado: (2015)

Usefulness and robustness of Immunoscore for personalized management of cancer patients
por: Marliot, Florence, et al.
Publicado: (2020)

Discovery and validation of the antimetastatic activity of citalopram in colorectal cancer
por: Iskar, Murat, et al.
Publicado: (2015)

Toll-like receptor genetic variants and colorectal cancer
por: Weber, Alexander NR, et al.
Publicado: (2014)

Immunological profiling as a means to invigorate personalized cancer therapy
por: Hegmans, Joost PJJ, et al.
Publicado: (2013)

BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
por: Herr, Ricarda, et al.
Publicado: (2015)

The role of FOXP3 in disease progression in colorectal cancer patients
por: Grimmig, Tanja, et al.
Publicado: (2013)

Stromal CEACAM1 expression regulates colorectal cancer metastasis
por: Arabzadeh, Azadeh, et al.
Publicado: (2012)

The consensus immunoscore: toward a new classification of colorectal cancer
por: Lanzi, Anastasia, et al.
Publicado: (2020)

Targeting copper metabolism to defeat KRAS-driven colorectal cancer
por: Aubert, Léo, et al.
Publicado: (2020)

Bioreactors get personal
por: Somerville, Robert P.T., et al.
Publicado: (2012)

Interleukin 21 impairs tumor immunosurveillance of colitis-associated colorectal cancer
por: Kesselring, Rebecca, et al.
Publicado: (2012)

DDR1 inhibition as a new therapeutic strategy for colorectal cancer
por: Sirvent, Audrey, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2us2kd9v1t15tlk8md3mhqpotq